Neuronal p38 MAPK Signaling Contributes to Cisplatin-Induced Peripheral Neuropathy
Antioxidants · 08.04.2025 · 14 (4) · 445
DOI: 10.3390/antiox14040445 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antioxidants, online erschienen am 08.04.2025. Verfasst von Yugal Goel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hematology/Oncology, Department of Medicine, University of California, Irvine, CA 92697, USA. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCCIH NIH HHS, NCI NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
This study investigates the role of p38 mitogen-activated protein kinase (MAPK) activation in dorsal root ganglion (DRG) neurons in the development and progression of chemotherapy-induced peripheral neuropathy (CIPN). This research evaluates whether inhibiting activation of p38 MAPK could reduce neuropathic outcomes in a transgenic breast cancer mouse model (C3TAg) and wild-type mice (FVB/N) treated with cisplatin. Cisplatin treatment stimulated p38 MAPK phosphorylation and nuclear translocation in DRG neurons. Neflamapimod, a specific inhibitor of p38 MAPK alpha (p38α), proven to be safe in clinical trials, inhibited neuronal cisplatin-induced p38 MAPK phosphorylation in vitro and in vivo. Neflamapimod also reduced cisplatin-induced oxidative stress, mitochondrial dysfunction, and cleaved caspase-3 expression in DRG neurons in vitro, protecting neuronal integrity and preventing axonal damage. Functionally, neflamapimod improved mechanical and musculoskeletal hyperalgesia, and cold sensitivity in cisplatin-treated mice, reversing neuropathic pain and neurotoxicity. This study identifies p38 MAPK activation as a critical driver of CIPN and highlights its potential as a therapeutic target for CIPN. Targeting p38 MAPK activation with neflamapimod offers a promising strategy to mitigate neurotoxicity and hyperalgesia without exacerbating cancer progression, positioning it as a novel intervention for CIPN.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hematology/Oncology, Department of Medicine, University of California, Irvine, CA 92697, USA.
- Department of Neurology, Department of Medicine, University of California, Irvine, CA 92697, USA.
- Chao Family Comprehensive Cancer Center, University of California, Irvine, CA 92697, USA.
- Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.
ORCID-Profile: Yugal Goel, Donovan A Argueta, Kristen Peterson, Daniela A Bota
Förderung
- NCCIH NIH HHS
- NCI NIH HHS
- NHLBI NIH HHS
- NCATS NIH HHS
- NIH grants
- Susan Samueli Scholar Award
- A.P. Giannini Foundation Fellowship
- NCATS/NIH TL-1 [5 TL1 TR 1415-8] training grant
Zitieren
APA
Goel, Y., Argueta, D. A., Peterson, K., Lomeli, N., Bota, D. A., & Gupta, K. (2025). Neuronal p38 MAPK Signaling Contributes to Cisplatin-Induced Peripheral Neuropathy. Antioxidants, 14(4), 445. https://doi.org/10.3390/antiox14040445
Vancouver
Goel Y, Argueta DA, Peterson K, Lomeli N, Bota DA, Gupta K. Neuronal p38 MAPK Signaling Contributes to Cisplatin-Induced Peripheral Neuropathy. Antioxidants. 2025;14(4):445. doi:10.3390/antiox14040445
BibTeX
@article{Goel2025,
author = {Goel, Yugal and Argueta, Donovan A and Peterson, Kristen and Lomeli, Naomi and Bota, Daniela A and Gupta, Kalpna},
title = {Neuronal p38 MAPK Signaling Contributes to Cisplatin-Induced Peripheral Neuropathy},
journal = {Antioxidants},
year = {2025},
volume = {14},
number = {4},
pages = {445},
doi = {10.3390/antiox14040445}
}
EUVIMED